U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H18FN3O2S.ClH.2H2O
Molecular Weight 395.877
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIPASUDIL HYDROCHLORIDE DIHYDRATE

SMILES

O.O.Cl.C[C@H]1CNCCCN1S(=O)(=O)C2=CC=CC3=C2C(F)=CN=C3

InChI

InChIKey=CMDJNMACGABCKQ-XVSRHIFFSA-N
InChI=1S/C15H18FN3O2S.ClH.2H2O/c1-11-8-17-6-3-7-19(11)22(20,21)14-5-2-4-12-9-18-10-13(16)15(12)14;;;/h2,4-5,9-11,17H,3,6-8H2,1H3;1H;2*1H2/t11-;;;/m0.../s1

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C15H18FN3O2S
Molecular Weight 323.386
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25414122 | http://dwti.co.jp/english/business-outline/product-pipeline/glanatec

Ripasudil (K-115) is a selective Rho-associated coiled coil-containing protein kinase (ROCK) inhibitor. This compound, which was originally discovered by D. Western Therapeutics Institute, Inc., reduces intraocular pressure (IOP) by directly acting on the trabecular meshwork, thereby increasing conventional outflow through the Schlemm's canal. As a result of this mechanism of action, ripasudil may offer additive effects in the treatment of glaucoma and ocular hypertension when used in combination with agents such as prostaglandin analogues (which increase uveoscleral outflow) and β blockers (which reduce aqueous production). GLANATEC® (Ripasudil hydrochloride hydrate) ophthalmic solution 0.4% is launched in Japan for the treatment of glaucoma and ocular hypertension.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 51.0 nM [IC50]
Inhibitor
8297
 19.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
GLANATEC

Approved Use

GLANATEC® (Ripasudil hydrochloride hydrate) ophthalmic solution 0.4% inhibits Rho kinase and promotes drainage of aqueous humor from main outflow. It consequently decreases intraocular pressure. It is usually used to treat glaucoma and ocular hypertension when other medicines for glaucoma have insufficient effect or can not be used.

Launch Date

1.41730565E12
Primary
Approved
8429
GLANATEC

Approved Use

GLANATEC® (Ripasudil hydrochloride hydrate) ophthalmic solution 0.4% inhibits Rho kinase and promotes drainage of aqueous humor from main outflow. It consequently decreases intraocular pressure. It is usually used to treat glaucoma and ocular hypertension when other medicines for glaucoma have insufficient effect or can not be used.

Launch Date

1.41730565E12
PubMed

PubMed

TitleDatePubMed
Ocular Penetration and Pharmacokinetics of Ripasudil Following Topical Administration to Rabbits.
2016 Sep
Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits.
2017
Patents

Patents

US8193193
3
WO2014174747
3

Sample Use Guides

In Vivo Use Guide
GLANATEC® (Ripasudil hydrochloride hydrate) ophthalmic solution 0.4% one drop twice daily
Route of Administration: Topical
In Vitro Use Guide
Ripasudil but not fasudil significantly reduced VEGF-induced MYPT-1 phosphorylation in human retinal microvascular endothelial cells (HRMECs) at 30 μmol/L. Ripasudil significantly inhibited VEGF-induced HRMECs migration and proliferation.
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:00:12 UTC 2023
Edited
by admin
on Sat Dec 16 11:00:12 UTC 2023
Record UNII
016TTR32QF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIPASUDIL HYDROCHLORIDE DIHYDRATE
WHO-DD  
Common Name English
1H-1,4-DIAZEPINE, 1-((4-FLUORO-5-ISOQUINOLINYL)SULFONYL)HEXAHYDRO-2-METHYL-, MONOHYDROCHLORIDE, DIHYDRATE, (2S)-
Common Name English
RIPASUDIL HYDROCHLORIDE HYDRATE [JAN]
Common Name English
GLANATEC
Brand Name English
RIPASUDIL HYDROCHLORIDE DIHYDRATE [MI]
Common Name English
K-115-R
Code English
K-115
Code English
RIPASUDIL HYDROCHLORIDE HYDRATE
JAN  
Common Name English
Ripasudil hydrochloride dihydrate [WHO-DD]
Common Name English
ISOQUINOLINE, 4-FLUORO-5-(((2S)-HEXAHYDRO-2-METHYL-1H-1,4-DIAZEPIN-1-YL)SULFONYL)-, HYDROCHLORIDE, HYDRATE (1:1:2)
Systematic Name English
Code System Code Type Description
FDA UNII
016TTR32QF
Created by admin on Sat Dec 16 11:00:12 UTC 2023 , Edited by admin on Sat Dec 16 11:00:12 UTC 2023
PRIMARY
DRUG BANK
DBSALT002191
Created by admin on Sat Dec 16 11:00:12 UTC 2023 , Edited by admin on Sat Dec 16 11:00:12 UTC 2023
PRIMARY
CAS
887375-67-9
Created by admin on Sat Dec 16 11:00:12 UTC 2023 , Edited by admin on Sat Dec 16 11:00:12 UTC 2023
PRIMARY
PUBCHEM
11625386
Created by admin on Sat Dec 16 11:00:12 UTC 2023 , Edited by admin on Sat Dec 16 11:00:12 UTC 2023
PRIMARY
SMS_ID
100000164209
Created by admin on Sat Dec 16 11:00:12 UTC 2023 , Edited by admin on Sat Dec 16 11:00:12 UTC 2023
PRIMARY
EVMPD
SUB178572
Created by admin on Sat Dec 16 11:00:12 UTC 2023 , Edited by admin on Sat Dec 16 11:00:12 UTC 2023
PRIMARY
MERCK INDEX
m11878
Created by admin on Sat Dec 16 11:00:12 UTC 2023 , Edited by admin on Sat Dec 16 11:00:12 UTC 2023
PRIMARY
Related Record Type Details
Structure of RIPASUDIL HYDROCHLORIDE ANHYDROUS
ANHYDROUS->SOLVATE
Structure of RIPASUDIL
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of RIPASUDIL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966